AR and neoplasm: The Lehmann classification has been reviewed after a better understanding of the immune-related tumor microenvironment and now includes the Basal-Like 1 and 2 (BSL 1 and 2), Mesenchymal (M), and Luminal Androgen Receptor (LAR) subtypes.